DeslaFlex is an innovative antidepressant formulation developed by Spektus using its proprietary Flexitab oral drug-delivery platform. The partnership aims to expand Lupin’s central nervous system (CNS) portfolio and provide unique treatment options for the management of major depressive disorder.
Under the agreement, Lupin will leverage its strong commercial footprint in Canada, while Spektus will contribute its capabilities in developing differentiated, novel formulations to introduce DeslaFlex in the market.Also Read: Lupin raises FY26 margin guidance to 27-28%
The collaboration is aimed at successfully launching DeslaFlex and establishing a platform for future launches. It also strengthens Lupin’s CNS portfolio with physician-endorsed, value-added therapies aligned with the regulatory environment in Canada.
Claus Jepsen, President, Global Specialty, Lupin, said, “This milestone reinforces our long-term commitment to advancing Lupin’s CNS footprint and deepens our commitment to Canadian healthcare. The addition of DeslaFlex™ to our portfolio provides patients and clinicians with much-needed flexibility in the management of Major Depressive Disorder, enabling clinicians to deliver more personalised, patient-focused care.”
Zarvaan Merchant, Chief Executive Officer of Spektus Pharma, said, “This partnership with Lupin represents a key milestone as Spektus transitions from development to commercial execution. Lupin’s global brand and established commercial strength in Canada make it an ideal partner to realise the full value of DeslaFlex for patients across this important market.”
Also Read: Lupin Q3 Results: Net profit up 38% on US sales surge and divestment gains
Shares of Lupin Ltd ended at ₹2,216.50, up by ₹17.30, or 0.79%, on the BSE.
(Edited by : Jomy Jos Pullokaran)
First Published: Feb 16, 2026 4:44 PM IST
Source link
#Lupin #signs #licence #supply #pact #Spektus #commercialise #DeslaFlex #Canada #CNBC #TV18
